Email this article Regulation of the Target Protein (Transgene) Expression in the Adenovirus Vector Using Agonists of Toll-Like Receptors
- Authors: Bagaev A.V.1, Pichugin A.V.1, Lebedeva E.S.1, Lysenko A.A.2, Shmarov M.M.2, Logunov D.Y.2, Naroditsky B.S.2, Ataullakhanov R.I.1, Khaitov R.M.1, Gintsburg A.L.2
-
Affiliations:
- National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia
- N.F. Gamaleya Research Institute of Epidemiology and Microbiology
- Issue: Vol 6, No 4 (2014)
- Pages: 27-39
- Section: Research Articles
- URL: https://actanaturae.ru/2075-8251/article/view/10522
- DOI: https://doi.org/10.32607/20758251-2014-6-4-27-39
- ID: 10522
Cite item
Abstract
Replication-defective adenoviral vectors are effective molecular tools for both gene therapy and gene vaccination. Using such vectors one can deliver and express target genes in different epithelial, liver, hematopoietic and immune system cells of animal and human origin. The success of gene therapy and gene vaccination depends on the production intensity of the target protein encoded by the transgene. In this work, we studied influence of Toll-like receptors (TLR) agonists on transduction and expression efficacy of adenoviral vectors in animal and human antigen-presenting cells. We found that agonists of TLR2, 4, 5, 7, 8 and 9 significantly enhance a production of the target protein in cells transduced with adenoviral vector having the target gene insert. The enhancement was observed in dendritic cells and macrophages expressing cytoplasmic (GFP), membrane (HA) or secretory (SEAP) proteins encoded by the respective rAd-vectors. Experiments in mice showed that enhancement of the transgene expression can be achieved in the organism of animals using a pharmaceutical-grade TLR4-agonist. In contrast to other TLR-agonists, the agonist of TLR3 substantially suppressed the expression of transgene in cells transduced with adenoviral vectors having insert of GFP or SEAP target genes. We propose that the enhancement of transgene expression is linked to the activation of MyD88→ NF-kB, while the inhibition of transgene expression depends on TRIF→ IRF signaling pathways. Both of these pathways jointly exploited by TLR4-agonists lead to the enhancement of transgene expression due to the dominant role of the MyD88→ NF-kB signaling.
About the authors
A. V. Bagaev
National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia
Author for correspondence.
Email: ravshan.ataullakhanov@gmail.com
Russian Federation
A. V. Pichugin
National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia
Email: ravshan.ataullakhanov@gmail.com
Russian Federation
E. S. Lebedeva
National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia
Email: ravshan.ataullakhanov@gmail.com
Russian Federation
A. A. Lysenko
N.F. Gamaleya Research Institute of Epidemiology and Microbiology
Email: ravshan.ataullakhanov@gmail.com
Russian Federation
M. M. Shmarov
N.F. Gamaleya Research Institute of Epidemiology and Microbiology
Email: ravshan.ataullakhanov@gmail.com
Russian Federation
D. Yu. Logunov
N.F. Gamaleya Research Institute of Epidemiology and Microbiology
Email: ravshan.ataullakhanov@gmail.com
Russian Federation
B. S. Naroditsky
N.F. Gamaleya Research Institute of Epidemiology and Microbiology
Email: ravshan.ataullakhanov@gmail.com
Russian Federation
R. I. Ataullakhanov
National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia
Email: ravshan.ataullakhanov@gmail.com
Russian Federation
R. M. Khaitov
National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia
Email: ravshan.ataullakhanov@gmail.com
Russian Federation
A. L. Gintsburg
N.F. Gamaleya Research Institute of Epidemiology and Microbiology
Email: ravshan.ataullakhanov@gmail.com
Russian Federation
References
- Arama C., Assefaw-Redda Y., Rodriguez A., Fernández C., Corradin G., Kaufmann S.H., Reece S.T., Troye-Blomberg M. // Vaccine. 2012, V.30, №27, P.4040-4045
- Hoft D.F., Blazevic A., Stanley J., Landry B., Sizemore D., Kpamegan E., Gearhart J., Scott A., Kik S., Pau M.G., Goudsmit J., McClain J.B., Sadoff J. // Vaccine. 2012, V.30, №12, P.2098-2108
- Scallan C.D., Tingley D.W., Lindbloom J.D., Toomey J.S., Tucker S.N. // Clin. Vaccine Immunol. 2013, V.20, №1, P.85-94
- Sharma A., Tandon M., Bangari D.S., Mittal S.K. // Curr. Drug ther. 2009, V.4, №2, P.117-138
- Drugs R. D. // INGN 201: Ad-p53, Ad5CMV-p53, adenoviral // gene therapy--introgen 2007, V.8, №3, url www.ncbi.nlm.nih.gov/ pubmed/17472413, P.53-54
- Pearson S., Jia H., Kandachi K. // Nat. Biotechnol. 2004, V.22, №1, P.3-4
- Ataullakhanov R.R., Shmarov M.M., Sedova E.S., Logunov D.Yu., Pichugin A.V., Ataullakhanov R.I., Khaitov R.M. // Patent WO2013129961 A1 RU . C07K16 / 10, A61P31 / 16, C12N15 / 44, C07K14 / 11, A61K39 / 145. 2012
- Shmarov M.M., Sedova E.S., Verkhovskaya L.V., Rudneva I.A., Bogacheva E.A., Barykova Y.A., Shcherbinin D.N., Lysenko A.A., Tutykhina I.L., Logunov D.Y., Smirnov Y.A., Naroditsky B.S., Gintsburg A.L. // Acta Naturae. 2010, V.2, №1, P.111-118
- Ataullakhanov R.I., Pichugin A.V., Shishkova N.M., Masternak T.B., Malkina E.Yu., Ulyanova L.I., Stetsenko O.N. // Immunologia. 2005, №2, P.111-120
- Melnikova T.M., Pichugin A.V., Ataullakhanov R.I., Khaitov R.M. // Patent Application RU 2013151824, priority date 21.11.2013. 2013
- Graham F.L., Prevec L. // Methods in Mol. Biol. 1991, V.7, P.109-127
- Berger J., Hauber J., Hauber R., Geiger R., Cullen B.R. // Gene. 1988, V.66, №1, P.1-10
- Newton K., Dixit V.M. // Cold Spring Harb. Perspect. Biol. 2012, V.4, №3
- Lim K.H., Staudt L.M. // Cold Spring Harb. Perspect. Biol. 2013, V.5, №1
- Lee Y., Sohn W.J., Kim D.S., Kwon H.J. // Eur. J. Biochem. 2004, V.271, №6, P.1094-105
Supplementary files
